We are live on ! Find out more
MRTX

Mirati Therapeutics, Inc. Common Stock
MRTX

Delisted

MRTX was delisted on the 22nd of January, 2024.

Back to rankings

81 hedge funds and large institutions have $757M invested in Mirati Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

146% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 13

85% more capital invested

Capital invested by funds: $408M → $757M (+$348M)

29% more funds holding

Funds holding: 63 → 81 (+18)

16% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 19

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

19% less call options, than puts

Call options by funds: $1.31M | Put options by funds: $1.62M

Holders
81
Holders Change
+18
Holders Change %
+28.57%
% of All Funds
1.86%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.11%
New
32
Increased
22
Reduced
19
Closed
13
Calls
$1.31M
Puts
$1.62M
Net Calls
-$308K
Net Calls Change
-$2.24M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$32.9M
2
CAM
Cormorant Asset Management
Massachusetts
+$19.1M
3
Millennium Management
Millennium Management
New York
+$10.6M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$9.08M
5
PC
PointState Capital
New York
+$8.29M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$27.9M
2
GTC
Ghost Tree Capital
New York
-$9.37M
3
PI
Putnam Investments
Massachusetts
-$6.83M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$5.4M
5
DM
Deerfield Management
New York
-$4.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$5.23M +$3.83M +137,901 +426%
Deutsche Bank
27
Deutsche Bank
Germany
$4.29M +$3.83M +138,113 +8,335%
ACP
28
Acuta Capital Partners
California
$3.07M -$1.53M -55,000 -35%
BCM
29
BlueCrest Capital Management
Jersey
$2.52M +$2.28M +82,085 New
RA
30
Royce & Associates
New York
$1.88M -$1.67M -60,000 -50%
EI
31
EAM Investors
California
$1.87M +$728K +26,212 +75%
UBS Group
32
UBS Group
Switzerland
$1.85M +$978K +35,233 +140%
Northern Trust
33
Northern Trust
Illinois
$1.85M +$144K +5,197 +9%
TEE
34
Tibra Equities Europe
United Kingdom
$1.75M +$1.58M +57,036 New
IHM
35
Iguana Healthcare Management
New York
$1.69M +$1.53M +55,000 New
Citadel Advisors
36
Citadel Advisors
Florida
$1.51M +$531K +19,128 +64%
OAM
37
Oxford Asset Management
United Kingdom
$1.47M +$380K +13,702 +40%
Susquehanna International Group
38
Susquehanna International Group
Pennsylvania
$1.45M +$1.31M +47,189 New
VEA
39
Virtus ETF Advisers
New York
$1.32M +$648K +23,350 +118%
Barclays
40
Barclays
United Kingdom
$1.23M +$616K +22,200 +123%
EGI
41
EAM Global Investors
California
$1.11M +$1.01M +36,335 New
LCM
42
Laurion Capital Management
New York
$1.07M +$966K +34,802 New
ECM
43
Element Capital Management
New York
$1M +$907K +32,680 New
PA
44
Perceptive Advisors
New York
$893K – – –
Citigroup
45
Citigroup
New York
$818K -$414K -14,901 -36%
TI
46
Trexquant Investment
Connecticut
$818K +$740K +26,650 New
CM
47
Crestline Management
Texas
$805K +$728K +26,212 New
Bank of New York Mellon
48
Bank of New York Mellon
New York
$753K +$190K +6,847 +39%
PP
49
PDT Partners
New York
$737K -$33.6K -1,209 -5%
Jacobs Levy Equity Management
50
Jacobs Levy Equity Management
New Jersey
$721K -$139K -5,000 -18%
1
2
3 4

MRTX Hedge Fund Activity: Q1 2018 in Review

81 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2018, worth a combined $757M — up 85% from $408M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new MRTX positions and 13 closed out — a net gain of 19 holders — while 22 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $32.9M. The largest seller was Broadfin Capital, cutting an estimated $27.9M.

  • 81 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2018, up from 63 in Q4 2017.
  • Funds reported $757M of Mirati Therapeutics, Inc. Common Stock stock for Q1 2018, up 85% quarter-over-quarter.
  • 32 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2018 and 13 closed out, a net change of +19 holders.
  • The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2018 was Fidelity Investments, an estimated $32.9M added.
  • The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2018 was Broadfin Capital, an estimated $27.9M sold.

Based on aggregated 13F filings for Q1 2018.